Superpower peptides available for pre-order. Get first access.

Peptide science

How does PE-22-28 compare to Selank?

PE-22-28 vs Selank compared by origin, proposed target, evidence stage, and regulatory status. Neither peptide is FDA-approved as of November 2026.

Quick answer

PE-22-28 and Selank are both seven amino acids long but unrelated. PE-22-28 is a spadin fragment tested only in cells and mice, with no registered human study as of November 2026. Selank is a tuftsin analog studied in small Russian trials, including three anxiety studies of 60 to 70 patients each. Neither is FDA-approved, and no trial has compared them.

Published
November 12, 2026
Last updated
November 12, 2026

PE-22-28 vs Selank at a glance

PE-22-28 and Selank are unrelated peptides at different stages of research. PE-22-28 is a shortened fragment of spadin1 tested in cells and mice. Selank is an analog of the immune peptide tuftsin, with small clinical studies in Russia2. Neither is an FDA-approved drug as of November 2026. Their origins, proposed targets, and research records barely overlap.

FeaturePE-22-28Selank
OriginShortened fragment of spadin1, designed in FranceTuftsin analog developed in Russia3
Length and sequence7 residues, GVSWGLR47 residues, TKPRPGP5
Proposed targetTREK-1 potassium channel6Several proposed pathways7 from lab and rat studies
Evidence modelHuman cell line and mice1Lab, rat, and small human studies8
Human evidenceNo human study registered9 as of November 2026Small Russian clinical studies10 with comparator drugs
FDA statusNot FDA-approved as of November 2026Not FDA-approved, flagged by FDA for compounding safety risks11
Russia statusNo approval, preclinical research compound12Registered as an anxiolytic13

PE-22-28 and Selank share a length of seven amino acids, but their origins and proposed targets differ.

PE-22-28 and Selank differ in origin and proposed target

PE-22-28 and Selank descend from different parent peptides and are proposed to act on different systems. A finding for one peptide therefore says nothing about the other.

Spadin came first, a peptide released from the sortilin propeptide14 that blocked TREK-1 channels in rodent cells and mice. TREK-1 is a potassium channel that helps set how excitable a nerve cell is6. PE-22-28 is one of the shortened spadin versions12 built by the same laboratory for potency and stability.

Selank is tuftsin, a short immune-signaling peptide15, extended at one end with three amino acids that slow its breakdown7. Researchers have proposed several mechanisms for Selank from laboratory and animal work.

Each proposal rests on a different lab or animal experiment, and most come from the institutes that developed Selank3. How much research stands behind each peptide is the more useful comparison.

PE-22-28 and Selank are at different research stages

Selank has been studied in a few small human trials, and PE-22-28 has not been studied in people. PE-22-28 and its parent peptide spadin have no registered human study9 as of November 2026.

In mice, four days of PE-22-28 reduced immobility in the forced swim test1 and increased new nerve-cell growth. Its developers described those mouse results as antidepressant activity.

One study of 62 patients compared Selank with medazepam8, an anxiety drug, and reported similar anxiety-reducing effects. Another compared Selank with the anxiety drug phenazepam2 in 60 patients. A third compared phenazepam alone with phenazepam plus Selank10 in 70 patients, so it cannot show what Selank does alone. None of the three abstracts describes placebo control or blinding. Rat work runs alongside, including a study of 24 rats20 in which the same heptapeptide reduced anxiety-like behavior over four weeks.

Those clinical studies include authors from the institute that developed Selank3. Outside Russia, Selank is still described as poorly studied21.

No trial has compared PE-22-28 with Selank in people, so neither peptide's results can be read across to the other. Their regulatory records differ as sharply as their research records.

Neither PE-22-28 nor Selank is FDA-approved

Neither PE-22-28 nor Selank is an FDA-approved drug as of November 2026, though Selank is approved in Russia for anxiety22. A drug that is not FDA-approved has not had its safety, effectiveness, or quality verified23 by FDA before it is marketed.

Selank acetate was nominated for use in US compounding, and that nomination was withdrawn. FDA said the substance may pose a risk for immunogenicity11, an unwanted immune response, from aggregation and peptide-related impurities. FDA also said that human safety information is lacking. Selank is also sold to US consumers as a dietary supplement21 and has turned up in seized preparations24 in Europe.

PE-22-28 remains a preclinical research compound, and what is known about PE-22-28's side effects comes from cells and animals.

Where can I learn about peptides?

Superpower’s peptide library is written and fact-checked by health journalists and licensed clinicians. Comparisons between two research peptides are easy to find and hard to check. The library covers PE-22-28, Selank, and the wider peptide families, including what has and has not been tested in people.

Two peptides of the same length can come from unrelated parents and be proposed to act on unrelated systems. That pattern is part of the science behind peptides.

IMPORTANT SAFETY INFORMATION

PE-22-28 and Selank are NOT FDA-approved for any medical use. Superpower Health does not prescribe, sell, compound, or facilitate access to either peptide. This page is provided for educational purposes only and does not constitute medical advice.

There are no human safety data for PE-22-28. Its published research is limited to cell and animal studies, no human clinical trial was registered as of November 2026, and its side effect profile, drug interactions, and long-term effects in humans are unknown. Selank's human data come from small studies in Russia. FDA has stated that it lacks important information about safety issues raised by selank acetate given to humans, and that compounded selank acetate may pose a risk of immunogenicity for certain routes of administration.

No FDA-approved label exists for either peptide, so no US prescribing information or formal contraindications exist. Findings for one peptide cannot be used to judge the safety of the other.

Products sold online as PE-22-28 or Selank, including those labeled for research use or sold as dietary supplements, have not had their identity, purity, sterility, or dosing verified by FDA before sale. Always consult a qualified healthcare provider before using any unapproved peptide.

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to PE-22-28 or Selank. PE-22-28 and Selank are not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

More peptide science